PYRIDINE DERIVATIVE INHIBITING RAF KINASE AND VESSEL ENDOTHELIUM GROWTH RECEPTOR RECEPTOR, METHOD FOR PRODUCING IT, PHARMACEUTICAL COMPOSITION CONTAINING IT AND ITS APPLICATION

• 收藏
• 分享

专利权人:

ИНЧХОН ЮНИВЕРСИТИ ИНДАСТРИ АКАДЕМИК КООПЕРЕЙШН ФАУНДЕЙШН (KR);САМДЖИН ФАРМАСЬЮТИКАЛ КО., ЛТД. (KR);БЕМИКЕМ КО., ЛТД. (KR)

发明人:

ЧХО, Ыи Хван (KR),СИН, Хи Чон (KR),КИ, Мин Хё (KR),КВОН, Хо Сок (KR),ЛИ, Че Вун (KR),ЧУ, Чон Хо (KR),ЛИ, Кын Кук (KR),КИМ, Чон Мин (KR),ПАК, Ён Пин (KR),КАН, Сун Хюн (KR),ЧХО, Хён Мин (KR),КИМ, Хюн Тэ

申请号：

RU2018131437

公开号：

RU2018131437A

申请日:

2017.01.11

申请国别(地区):

RU

年份:

2020

代理人:

摘要：

The present invention provides a novel pyridine derivative, a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient. The pyridine derivative according to the present invention inhibits Raf kinase (B-Raf, Raf-1, or B-RafV600E) and a vascular endothelial growth factor receptor (VEGFR2) involved in angiogenesis, and thus, can be favorably used for the prevention or treatment of melanoma, colorectal cancer, prostate cancer, thyroid cancer, lung cancer, pancreatic cancer, ovarian cancer, or the like, which is induced by RAS mutation.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/